Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 5
1992 1
1993 1
1994 5
1995 5
1996 1
1997 1
1998 2
1999 3
2000 1
2002 1
2007 1
2008 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.
Ring BJ, Parli CJ, George MC, Wrighton SA. Ring BJ, et al. Drug Metab Dispos. 1994 May-Jun;22(3):352-7. Drug Metab Dispos. 1994. PMID: 8070310
The major in vivo human metabolite of zatosetron is 8-alpha-methyl,8-beta-oxo zatosetron [N-O (1) zatosetron]. N-Desmethyl zatosetron (NdM zatosetron) and 3-hydroxy-zatosetron (3-OH-zatosetron) are minor human metabolites. ...
The major in vivo human metabolite of zatosetron is 8-alpha-methyl,8-beta-oxo zatosetron [N-O (1) zatosetron]. N-Desmet …
Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E. Bendele A, et al. Drug Chem Toxicol. 1995 Feb;18(1):61-82. doi: 10.3109/01480549509017858. Drug Chem Toxicol. 1995. PMID: 7768200
A 1-year chronic toxicity study was conducted in which rhesus monkeys (4/sex/dose) were given daily doses of 0, 3, 10, or 25 mg zatosetron/kg by nasogastric intubation. Clinical signs of toxicity characterized by salivation, diarrhea or soft stools, and/or emesis occurred …
A 1-year chronic toxicity study was conducted in which rhesus monkeys (4/sex/dose) were given daily doses of 0, 3, 10, or 25 mg zatosetro …
Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
Chappell AS, Bay JM, Botzum GD, Cohen ML. Chappell AS, et al. Neuropharmacology. 1994 Mar-Apr;33(3-4):509-13. doi: 10.1016/0028-3908(94)90082-5. Neuropharmacology. 1994. PMID: 7984290 Clinical Trial.
Groups receiving zatosetron and placebo were demographically similar and zatosetron was well-tolerated in all patients with no clinically significant adverse effects. Migraine severity was reduced in both the placebo and zatosetron groups with no statisticall …
Groups receiving zatosetron and placebo were demographically similar and zatosetron was well-tolerated in all patients with no …
Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.
Franz PM, Mattiuz EL, Hatcher BL, DeSante KA, Breau AP, Occolowitz JL, Dorman DE, Schmid CR, Goldberg MJ, Rubin A. Franz PM, et al. Drug Metab Dispos. 1993 Mar-Apr;21(2):249-54. Drug Metab Dispos. 1993. PMID: 8097693
In serum, the parent compound represented about 85% of the radioactivity, zatosetron-N-oxide represented 10%, and N-desmethyl-zatosetron and 3-hydroxy-zatosetron each represented 2-3%. ...In urine, approximately 45% of the radioactivity was unchanged zatos …
In serum, the parent compound represented about 85% of the radioactivity, zatosetron-N-oxide represented 10%, and N-desmethyl-zato …
Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
Gidda JS, Evans DC, Cohen ML, Wong DT, Robertson DW, Parli CJ. Gidda JS, et al. J Pharmacol Exp Ther. 1995 May;273(2):695-701. J Pharmacol Exp Ther. 1995. PMID: 7752072
Zatosetron and zatosetron-QUAT showed high affinity and selectivity for 5-HT3 receptors in radioligand binding studies. ...Zatosetron-QUAT (0.01-1.0 mg/kg i.v.) had no effect. [14C]-zatosetron-QUAT (100 micrograms/kg) was not detected in the brain afte …
Zatosetron and zatosetron-QUAT showed high affinity and selectivity for 5-HT3 receptors in radioligand binding studies. ... …
[Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles].
Miyata K, Honda K. Miyata K, et al. Nihon Yakurigaku Zasshi. 1994 Sep;104(3):143-52. doi: 10.1254/fpj.104.143. Nihon Yakurigaku Zasshi. 1994. PMID: 7959407 Review. Japanese.
Recently, many selective 5-HT3-receptor antagonists including tropisetron, zacopride, ondansetron, granisetron, zatosetron, nazasetron, YM060 and YM114 (KAE-393) have been developed. ...
Recently, many selective 5-HT3-receptor antagonists including tropisetron, zacopride, ondansetron, granisetron, zatosetron, nazasetro …
Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
Schwartz SM, Goldberg MJ, Gidda JS, Cerimele BJ. Schwartz SM, et al. J Clin Pharmacol. 1994 Mar;34(3):250-4. doi: 10.1002/j.1552-4604.1994.tb03994.x. J Clin Pharmacol. 1994. PMID: 7517409 Clinical Trial.
In separate randomized, placebo-controlled trials, 20 dogs received zatosetron intravenously and eight healthy men received zatosetron (50 mg) orally, followed by ipecac syrup. ...In men, zatosetron administration resulted in fewer emetic episodes after ipeca …
In separate randomized, placebo-controlled trials, 20 dogs received zatosetron intravenously and eight healthy men received zatose …
The human drug metabolizing cytochromes P450.
Wrighton SA, VandenBranden M, Ring BJ. Wrighton SA, et al. J Pharmacokinet Biopharm. 1996 Oct;24(5):461-73. doi: 10.1007/BF02353474. J Pharmacokinet Biopharm. 1996. PMID: 9131485 Review.
Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety.
Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME. Smith WT, et al. J Clin Psychopharmacol. 1999 Apr;19(2):125-31. doi: 10.1097/00004714-199904000-00006. J Clin Psychopharmacol. 1999. PMID: 10211913 Clinical Trial.
Patients were randomly assigned to either a fixed oral dose of 0.2, 1, or 5 mg of zatosetron or placebo for 4 weeks, followed by a 2-week placebo phase. ...There were no deaths or serious AEs reported in this study. This pilot study demonstrated that zatosetron at d …
Patients were randomly assigned to either a fixed oral dose of 0.2, 1, or 5 mg of zatosetron or placebo for 4 weeks, followed by a 2- …
Zatosetron. (LY 191617, LY 277359).
[No authors listed] [No authors listed] Drugs R D. 1999 Dec;2(6):397-9. doi: 10.2165/00126839-199902060-00009. Drugs R D. 1999. PMID: 10763451 No abstract available.
28 results